UNIT vs AMLX Comparison

Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 240,000 route-mile fiber network that serves enterprise and residential customers. Selling high-capacity fiber circuits to enterprises generates about 20% of consolidated revenue. Uniti's residential networks reach about 4.5 million households, mostly in less-populated markets in the Southeast, but only about 1.9 million of these locations have been upgraded with fiber. Legacy copper-cable networks serve the remainder. Residential services account for about a third of total revenue. Small business and wholesale services provided within this residential service territory account for about 20% of revenue.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.